There is a clear trend of success among those trials including biomarker selection (25.9%) compared with those lacking selection biomarkers (8.4%). 164 There are several methods that can be used to reduce failure rates, such as early identification of false drug candidates, stratification of patients, development of diagnostics, proper use of pharmacogenomics through machine learning, and other analysis tools that can provide improvements and efficiencies in patient categorization.
1
—
—